Elevance Health, Inc. $ELV Shares Sold by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab decreased its holdings in Elevance Health, Inc. (NYSE:ELV) by 15.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 367,049 shares of the company’s stock after selling 67,500 shares during the quarter. Elevance Health makes up 1.9% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 16th biggest holding. Danica Pension Livsforsikringsaktieselskab’s holdings in Elevance Health were worth $128,669,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP raised its holdings in Elevance Health by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after purchasing an additional 303,099 shares during the period. Artisan Partners Limited Partnership raised its holdings in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC raised its holdings in Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after purchasing an additional 798,457 shares during the period. Finally, Invesco Ltd. raised its holdings in Elevance Health by 22.9% in the 3rd quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after purchasing an additional 484,303 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $376.39 on Friday. The business has a 50 day simple moving average of $310.69 and a two-hundred day simple moving average of $331.90. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $424.24. The stock has a market capitalization of $81.74 billion, a P/E ratio of 16.01, a PEG ratio of 2.25 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the prior year, the firm earned $11.97 earnings per share. The business’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts predict that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Analysts Set New Price Targets

ELV has been the subject of a number of analyst reports. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and upped their price target for the stock from $405.00 to $435.00 in a report on Wednesday. Leerink Partners set a $364.00 target price on Elevance Health in a report on Thursday, April 23rd. Barclays increased their target price on Elevance Health from $393.00 to $408.00 and gave the company an “overweight” rating in a report on Friday, April 24th. Finally, Mizuho reduced their target price on Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. Thirteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $384.58.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.